CURRICULUM VITAE. Richard A. Nash, M.D.

Transcription

1 Name: Present Title/Affiliation: Physician, Colorado Blood and Cancer Institute Birthplace: Citizenship: Winnipeg, Manitoba, Canada United States of America Home Address: 9137 E 28 th Place, Denver CO Telephone Office Address: 1721 E. 19 th Ave, #300, Denver, CO Telephone Education: 1973 Pre-Med., University of Manitoba 1977 M.D. Degree, University of Manitoba Postgraduate Training: Intern, Manitoba Affiliated Teaching Hospitals (M.A.T.H.), Univ. of Manitoba Resident, Internal Medicine, M.A.T.H., Univ. of Manitoba 2-5/1983 Clinical studies in sexually transmitted diseases, Nairobi, Kenya Fellow, Hematology and Oncology, M.A.T.H., Univ. of Manitoba 2-3/1986 Bone Marrow Transplant Service, Fred Hutchinson Cancer Research Center, Seattle, WA Fellow, Medical Research Council Award, Fred Hutchinson Cancer Research Center, Seattle, WA Faculty Positions: Assistant Member, Fred Hutchinson Cancer Research Center, Seattle, WA Assistant Professor of Medicine, University of Washington School of Medicine, Seattle, WA Associate Member, Fred Hutchinson Cancer Research Center, Seattle, WA Associate Professor of Medicine, University of Washington School of Medicine, Seattle, WA Member, Fred Hutchinson Cancer Research Center, Seattle, WA Professor of Medicine, University of Washington School of Medicine, Seattle, WA Affiliate Investigator, Fred Hutchinson Cancer Research Center and University of Washington, Seattle WA Hospital Positions: Emergency Physician, Grace Hospital, Winnipeg, Canada Travel and Locum Tenens Medical Staff Member, Swedish Medical Center, Seattle, WA Medical Staff Member, University of Washington Medical Center, Seattle, WA Medical Staff Member, Seattle Cancer Care Alliance (SCCA), 2011-Present Medical Staff Member, HCA-HealthONE Presbyterian/St. Luke s Medical Center Honors: Fellowship Award, Medical Research Council of Canada 1

2 Professional Certifications: 1977 Licentiate of the Medical Council of Canada (L.M.C.C.) 1978 National Board Examination for U.S.A Internal Medicine, Fellow of the Royal College of Physicians and Surgeons of Canada 1985 Diplomate, Internal Medicine, American Board of Internal Medicine 1986 Specialty Certification: Medical Oncology, Royal College of Physicians and Surgeons of Canada 1986 Specialty Certification: Hematology, Royal College of Physicians and Surgeons of Canada 1993 Diplomate, Medical Oncology, American Board of Internal Medicine Medical Practice License: Licensed, College of Physicians and Surgeons of Manitoba 1986-present Licensed, Washington State Board of Medical Examiners 2011-present Licensed, Colorado Medical Board Society Memberships: Member, Manitoba Medical Association Member, American Society of Hematology Member, American Society for Blood and Marrow Transplantation Member, American Society for Clinical Oncology Teaching Responsibilities: 1. Previous Research Trainees: Peter McSweeney M.D Fellow, Associate in Clinical Research, Assistant Member George Georges M.D Fellow, Associate in Clinical Research, Assistant Member Benedetto Bruno M.D Visiting Investigator George Mathioudakis M.D Fellow German Espino M.D Visiting Investigator Fabrizio Carnevale M.D Visiting Investigator Federico Viganego M.D Visiting Investigator Young-Don Joo M.D Visiting Investigator Yang-Soo Kim M.D Visiting Investigator Dario Sangiolo M.D Visiting Investigator Anna Taranova M.D Postdoctoral Fellow Murad Yunusov M.D Research Associate Cristina Castilla M.D Postdoctoral Fellow 2. Clinical Instruction for Medical Students, Residents, Fellows and Physicians Assistants for the FHCRC/SCCA Hematopoietic Cell Transplantation Unit as Attending Physician (2 months/year) Special National Responsibilities Committees Blood and Marrow Transplantation Clinical Trials Network, Acute GVHD Subcommittee (Member) Center for International Blood & Marrow Transplant Research, Autoimmune Disease Working Committee (Chair) 2

3 National Clinical Trials: Chair/Steering Committee 2004-present 2004-present Protocol title: A Randomized, Open-Label, Phase II/III Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation with Auto-CD34+HPC versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis; (Scleroderma: Cyclophosphamide or Transplant (SCOT)) Sponsor: NIAID Responsibility: Co-Chair, Steering Committee Protocol title: A Phase II Study of High-Dose Immunosuppressive Therapy (HDIT) Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin, and Autologous CD34+ Hematopoietic Stem Cell Transplant (HCT) for the Treatment of Poor Prognosis Multiple Sclerosis; High dose immunosuppression and AutoLogous Transplantation for Multiple Sclerosis (HALT MS) Study Sponsor: NIAID/Conducted by the Immune Tolerance Network Responsibility: Chair Special National Responsibilities Member Clinical Oncology Study Section, NIH Special Local Responsibilities Committees Canine Facility Users Committee, Fred Hutchinson Cancer Research Center Institutional Review Board (IRB), Fred Hutchinson Cancer Research Center Appointments and Promotions Committee, Clinical Research Division, Fred Hutchinson Cancer Research Center Research Funding: Current N01 AI 15416, ITN/UCSF (P.I.: Nash, R.) Effort 1.20 cal mos Funding period: 1/1/2006 2/28/2013 A Phase I/II Study of High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for the Treatment of Poor Prognosis Multiple Sclerosis FND RG 4183-A-2, NMSS (P.I.: Nash, R) Funding period: 7/1/2009 6/30/2012 Allogeneic HSCT in MS Patients: International Registry Effort 0.6 cal mos FND TE 5103, SRF (P.I.: Nash, R.) Effort: 0.30 cal mos Funding period: 9/17/09-4/30/12 Hematopoietic Cell Transplantation for Scleroderma National and International Activities 3

4 Invitations to Speak 1. Invited Speaker: Early results from the HALT MS Clinical Trial. Annual Meeting of the Consortium of Multiple Sclerosis Centers, Montreal, Quebec; June 2, Invited Speaker: A Phase II Study of High-Dose Immunosuppressive Therapy (HDIT) Using Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) + Thymoglobulin, and Autologous CD34+ Hematopoietic Stem Cell Transplant (HCT) for the Treatment of Poor Prognosis Multiple Sclerosis. Annual Meeting of the American Society of Blood and Marrow Transplantation, Honolulu, HI; February 19, Invited Speaker: Immunosuppression and Malignancies. EMD Serono Medical Oncology Expert Panel Meeting, Boston, MA; December 10-11, Invited Speaker: Transplants for Autoimmune Disease: Current Status. Presbyterian/St. Lukes Medical Center, Denver, CO; August 13, Invited Speaker: Large Animal Models of Cell Based Therapies. Annual Meeting of the International Society of Cellular Therapy, Philadelphia, PA; May 25, Invited Speaker: Hematopoietic Cell Transplantation for Scleroderma. Rheumatology Grand Rounds, University of Washington, Seattle, WA; May 18, Invited Speaker: Hematopoietic Cell Transplantation for Scleroderma? Annual Meeting of the Scleroderma Research Foundation Meeting, San Francisco, CA; March 15, Invited Speaker: 1. Patient Management Strategies: Malignancies, Transfusion, Myelodysplastic Syndrome. 2. Screening Patients Prior to Treatment with Cladribine Tablets, EMD Serono Medical Advisory Board Meeting Patient Surveillance and Management Recommendations for Physicians, Coral Gables, FL; December 5, Invited Speaker: Hematopoietic Cell Transplantation for Severe Autoimmune Disease: Role of Allogeneic Stem Cell Transplantation. Hematopoietic Stem Cell Transplantation for Severe Autoimmune Diseases, Florence, Italy; November 20, Invited Speaker: Hematopoietic Cell Transplantation for Multiple Sclerosis. National Multiple Sclerosis Society (Washington Chapter), Seattle, WA; October 13, Invited Speaker: Treatment of Systemic Sclerosis: What Role for Hematopoietic Cell Transplantation? Annual Meeting of the Scleroderma Research Foundation, San Francisco, CA; April 5, Invited Speaker: Allogeneic Hematopoietic Cell Transplantation in Patients with Multiple Sclerosis. NIHsponsored Multiple Sclerosis workshop, Minneapolis, MN; November 9-10, Invited Speaker: Is There a Role for Hematopoietic Stem Cell Transplantation in Autoimmune Neurological Diseases; 9 th International Congress of Neuroimmunology, Fort Worth, TX; October 27, Invited Speaker: Regulatory Immune Response in a Large Animal Transplantation Model University of Virginia, Charlottesville, VA; April 23, Invited Speaker: Treatment of Autoimmune Diseases: What Role for Hematopoietic Cell Transplantation. University of Virginia, Charlottesville, VA; December 13, Invited Speaker: Hematopoietic Cell Transplantation for Multiple Sclerosis. Cleveland Clinic, Cleveland, OH. September 17, Invited Speaker: Current and Future Treatments for GVHD. and Hematopoietic Cell Transplantation for Severe Autoimmune Diseases: Systemic Sclerosis. Kyushu University, Fukuoka, Japan; July 21, Invited Speaker: Meet the Specialist- Current and Future Treatments for GVHD. Marunouchi Building Hall & Conference Square, Tokyo, Japan. July 19, Invited Speaker: Hematopoietic Cell Transplantation for Severe Autoimmune Diseases: Systemic Sclerosis. University of Miami, Miami, FL; May 22, Invited Speaker: Hematopoietic Cell Transplantation for Severe Autoimmune Diseases. and Update on the Latest BMT Protocol: Conditioning Regimens. Cigna Lifesource Spring Seminar, Pittsburgh, PA; March 24, Invited Speaker: Hematopoietic Cell Transplantation for Severe Autoimmune Diseases: Systemic Sclerosis. South Lake Union, University of Washington, Seattle; March 15, Invited Speaker: Hematopoietic Cell Transplantation for Severe Autoimmune Diseases: Systemic Sclerosis. Georgetown University, Washington D.C., February 15, Speaker: Topic- High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Severe Systemic Sclerosis: Long-Term Follow-up of US Multicenter Pilot Study. 4

5 American College of Rheumatology Annual Meeting, Washington DC, November 12, Invited Speaker: Topic- Hematopoietic Cell Transplantation for Autoimmune Diseases, World Transplant Congress, Boston, MA; July 25, Invited Speaker: Topic- Hematopoietic Cell Transplantation for Multiple Sclerosis, Consortium of Multiple Sclerosis Centers (CMSC), Scottsdale, AZ; May 31, Speaker: High-dose Immunosuppressive Therapy and Hematopoietic Cell Transplantation for Autoimmune Diseases, Annual Meeting of the American Association of Blood Banks, Seattle, WA; October 18, Speaker: Rationale for Allogeneic Stem Cell Transplant for Treatment of Autoimmune Disease: Graft-versus- Autoimmunity and A Phase II Study of High-Dose Immunosuppressive Therapy (HDIT) Using Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) + Thymoglobulin, and Autologous CD34+ Hematopoietic Stem Cell Transplant (HCT) for the Treatment of Poor Prognosis Multiple Sclerosis (DAIT/NIAID/ITN), Cellular Therapy for Treatment of Autoimmune Disease: Basic Science and Clinical Studies Including New Developments in Hematopoietic and Mesenchymal Stem Cell Therapy (sponsored by City of Hope), Newport Beach, CA; October 5-7, Speaker: Stem Cells and Multiple Sclerosis, Annual Meeting of the American Association of Immunologists, San Diego, CA; April 4, Speaker: Autoimmune Diseases and Allogeneic Hematopoietic Cell Transplantation: The Experience so Far. 31 st Annual Meeting of the European Group for Blood and Marrow Transplantation. Prague, Czech Republic, March 21, Speaker, Co-Chair and Co-Organizer: Hematopoietic Cell Transplantation for Systemic Sclerosis. NIHsponsored workshop entitled Feasibility of Allogeneic Hematopoietic Stem Cell Transplantation for Autoimmune Disease. Washington DC, March 12 and 13, Speaker: Acute and Chronic GVHD: Prevention and Treatment 10 th Anniversary of the Hematology-Oncology Transplantation Center, Panama City, Panama. Sept 17, Speaker: Blood/Marrow Transplant Strategies for Autoimmune Diseases. The 6 th Annual: Evolving Science of Blood/Marrow Transplantation and Cancer Treatments, March 25,2004, Scottsdale, AZ. 33. Speaker: New Approaches to the Treatment of GVHD: MMF Tandem BMT (ASBMT) Meetings, February 13, 2004, Orlando, FL. 34. Speaker: New Strategies for the Treatment and Prevention of PCP and Other Opportunistic Infections Following Stem Cell Transplantation: EBV-Associated PTLD ASH Meeting, December 5, 2003, San Diego, CA. 35. Speaker: Immune Recovery After HSCT Changing Risks for Opportunistic Infections. Tandem BMT Meetings, ASBMT/IBMTR, February 2, 2003, Keystone Resort, CO. 36. Speaker: Allogeneic HSCT for Severe Autoimmune Diseases. Stem Cell Therapy and Autoimmune Diseases Conference, July 13-15, 2002, Snowbird, UT. 37. Invited Speaker: Allogeneic Hematopoietic Stem Cell Transplantation: Can the Sword Become a Scalpel? Institute for Cancer Research and Treatment, University of Torino Medical School, November 30, 2001, Torino, Italy. 38. Invited Speaker: Hematopoietic Stem Cell Transplantation for Severe Autoimmune Disease, Nonmyeloablative Stem Cell Transplantation: Exploiting the Graft-versus-Host Reaction in the Treatment of Malignant and Non- Malignant Diseases, Graft-versus-Host Disease: Diagnosis and Treatment. Congress Meeting of the Caja de Seguro Social de Panama, November 15-17, 2001, Panama City, Panama. 39. Invited Speaker: US-Seattle Results and U.S. Protocol for MS. Conference: Hematopoietic Stem Cell Transplantation in Autoimmune Diseases, October 3-6, 2001, City of Hope, CA. 40. Invited Speaker: Non-Myeloablative Transplantation. Acute Leukemias IX, February 24-28, 2001, Munich, Germany. 41. Oral Presentation: Treatment of Severe MS with HDIT and Autologous Stem Cell Transplantation. American Society of Hematology, December 1-5, 2000, San Francisco, CA. 42. Invited Speaker: Treatment of Severe MS with HDIT and Autologous Stem Cell Transplantation. Americas Committee for Treatment and Research in Multiple Sclerosis, October 15, 2000, Boston, MA. 43. Invited Speaker: Treatment of Severe MS with HDIT and Autologous Stem Cell Transplantation. Hematopoietic Stem Cell Therapy in Autoimmune Diseases, October 5-7, 2000, Basel, Switzerland. 44. Invited Speaker: Hematopoietic Stem Cell Transplantation for Treatment of Malignant and NonMalignant Diseases: Leaving the Nuclear Age Behind. IVIIIth International Congress of the Transplantation Society, August 27 - September 1, 2000, Rome, Italy 5

6 45. Tandem BMT Meeting, IBMTR/ASBMT, March 26 - April 1, 2000, Anaheim, CA, Invited Speaker Current Perspectives on the Role of Non-Myeloablative Allografts. Developing the Future, January 28, 2000, Mount Juliet, Ireland A. Invited Speaker Update on High-Dose Immunosuppressive Therapy for MS. Autoimmune Diseases Working Committee B. Chair, Clinical GVHD Workshop C. Invited Speaker New T Cell Activation Inhibitors for Prevention of Acute GVHD after URD Transplants. Satellite Breakfast Symposium 46. Invited speaker Uses for Cytotoxic Agents in Autoimmune Diseases. Immune-Based Therapies: The Coming of Age. 41 st ASH Annual Meeting, December 3, 1999, New Orleans, LA. 47. Invited Speaker Low Dose Conditioning to Induce Mixed Chimerism after Stem Cell Transplantation. United Resources Network 8 th Annual National Clinical Conference, October 5, 1999, Minneapolis, MN. 48. Invited Speaker Low Dose Conditioning to Induce Mixed Chimerism after Stem Cell Transplantation. European Group for Blood and Marrow Transplantation, March 23, 1999, Hamburg, Germany 49. Invited Speaker Low Dose Conditioning to Induce Mixed Chimerism after Stem Cell Transplantation. Benjamin Franklin Spring Symposium, February 20, 1999, Berlin, Germany 50. Invited Speaker Novel Approaches to Treatment of GVHD in BMT. NMDP Symposium, December 5, 1997, San Diego, CA. 51. Invited Speaker Delayed Platelet Recovery or Late Failure after Hematopoietic Stem Cell Transplantation: Risk Factors and Significance. American Society of Hematology Annual Meeting. December 6, 1996, Orlando, FL. 52. Invited Speaker, "Thrombocytopenia after Hematopoietic Cell Transplantation," Molecular Regulation of Platelet Production, Keystone Symposia; February, Invited Speaker on the topic of chronic GVHD, Blood Cell and Bone Marrow Transplants, Keystone Symposia; January,